In breast cancer, febrile neutropenia-related admissions account for significant mortality
the ONA take:
According to a new study published in the journal Supportive Care in Cancer, researchers from the Reading Health System Department of Internal Medicine in West Reading, Pennsylvania, have found that febrile neutropenia-related hospitalizations still account for significant health care resource use, morbidity, and mortality among patients with breast cancer.
For the retrospective study, researchers sought to investigate the mean length of stay, incidence of morbidity and mortality, and health care costs associated with febrile neutropenia-related admissions of patients with breast cancer.
Researchers identified patients with breast cancer who were hospitalized for febrile neutropenia between 2009 and 2011 from the Nationwide Impact Sample database. Results showed that the mean length of stay was 5.7 days (95% CI: 5.5 - 5.9) and the mean cost of hospitalization was $37,087 (95% CI: 34,009 - 40,165).
They found that the average inhospital mortality rate during that period was 2.6% (n = 685), and age 65 years and older was associated with a higher risk of mortality (4.4% vs 1.7%; OR = 2.7; 95% CI: 2.3 - 3.1; P < 0.01). The findings suggest that febrile neutropenia accounts for significant mortality, and more effort needs to be made to reduce the cost of health care without decreasing the quality of care.
Febrile neutropenia-related hospitalizations still account for morbidity, and mortality among patients with breast cancer.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|